Checkmate Pharmaceuticals
Developing a new approach for cancer immunotherapy.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD525—788m (Dealroom.co estimates Jun 2020.)
Cambridge Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$20.0m | Series A | ||
$27.0m | Series B | ||
* | $22.0m | Late VC | |
N/A | $16.0m | Early VC | |
$85.0m | Series C | ||
* | $250m | Acquisition | |
Total Funding | AUD263m |
Related Content
Recent News about Checkmate Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.